Status:
COMPLETED
A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma
Lead Sponsor:
Jules Bordet Institute
Conditions:
Ovarian Carcinoma
Relapse
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
This is a Phase II study for recurrent ovarian carcinoma platinum-sensitive and resistant tumors Folfox regimen.
Detailed Description
Evaluation of the safety and the efficacy of a combination of oxaliplatin and 5FU (Folfox) in patients with ovarian carcinoma relapsing either after platinum-combined regimen. The Folfox regimen is a...
Eligibility Criteria
Inclusion
- ovarian carcinoma relapse
Exclusion
- neurotoxicity grade III renal clearance \< 60 ml/min
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2014
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT01481701
Start Date
October 1 2008
End Date
May 1 2014
Last Update
October 15 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Jules Bordet
Brussels, Belgium, 1000